Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update
Open Access
- 1 April 2024
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 299-310
Abstract
Introduction: Medullary thyroid carcinoma (MTC), a rare malignancy, requires early diagnosis for optimal patient outcomes. An important aspect of MTC diagnosis is the assessment of serum biomarkers. This review aimed to evaluate the use of serum biomarkers in the diagnosis, prognosis, and follow-up of MTC. Methods: A thorough search of PubMed covering 1975 to 2022 was conducted to identify English-language articles on MTC serum biomarkers. Results: The review revealed that calcitonin (Ctn) and carcinoembryonic antigen (CEA) remain the most important serum biomarkers for MTC diagnosis and management. Despite limited studies on procalcitonin (PCT), its stability and ability to exclude interference from inflammation make it a valuable potential marker of MTC. Although the positive rate of serum CA19-9 levels in MTC patients was not high, it can be used as an indicator of poor prognosis in advanced MTC. Other serum markers, including chromogranin A, gastrin-releasing peptide precursor, and neurospecific enolase, did not show any unique value in MTC diagnosis and management. Conclusion: Taken together, this review emphasized the importance of serum biomarkers, particularly Ctn and CEA, in the diagnosis and management of MTC. PCT shows promise as a valuable potential marker, whereas CA19-9 can be used as a prognostic indicator of advanced MTC. Further research is needed to validate the significance of these serum biomarkers in MTC and determine the effects of confounding factors on their levels. Clinicians should consider using these markers in MTC diagnosis, prognosis, and follow-up, particularly for patients with advanced disease.Keywords
This publication has 114 references indexed in Scilit:
- Combining serum calcitonin, carcinoembryonic antigen, and neuron‐specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinomaJournal of Clinical Laboratory Analysis, 2020
- Prediction of biochemical cure in patients with medullary thyroid cancerBritish Journal of Surgery, 2020
- Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancerBritish Journal of Surgery, 2019
- Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrenceHead & Neck, 2016
- Calcitonin measurement on fine needle washouts: Preanalytical Issues and Normal Reference ValuesDiagnostic Cytopathology, 2011
- Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancerCancer, 2009
- Abnormal Carcinoembryonic Antigen Levels and Medullary Thyroid Cancer ProgressionArchives of Surgery, 2007
- Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinomaCancer, 1984
- Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of diseaseCancer, 1984
- Identification of carcinoembryonic antigen in the C-Cell of the normal thyroidCancer, 1980